Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2017 - 2025)

Historic Non-Current Deferred Tax Liability for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Q3 2025 value amounting to $273000.0.

  • Lineage Cell Therapeutics' Non-Current Deferred Tax Liability changed 0.0% to $273000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $273000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $273000.0 for FY2024, which is 0.0% changed from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $273000.0 for Q3 2025, which was down 0.0% from $273000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability peaked at $2.1 million during Q1 2021, and registered a low of $273000.0 during Q1 2023.
  • Its 5-year average for Non-Current Deferred Tax Liability is $961052.6, with a median of $273000.0 in 2023.
  • In the last 5 years, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability skyrocketed by 13221.48% in 2022 and then plummeted by 8684.97% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $2.1 million in 2021, then changed by 0.0% to $2.1 million in 2022, then tumbled by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then changed by 0.0% to $273000.0 in 2025.
  • Its last three reported values are $273000.0 in Q3 2025, $273000.0 for Q2 2025, and $273000.0 during Q1 2025.